{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T13:19:01Z","timestamp":1795094341852,"version":"4.10.2"},"reference-count":172,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100007446","name":"King Khalid University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007446","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Oncology"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.seminoncol.2025.152454","type":"journal-article","created":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T00:15:34Z","timestamp":1764720934000},"page":"152454","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Immuno-oncology approaches to overcome T cell exhaustion in melanoma"],"prefix":"10.1016","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-8969-3888","authenticated-orcid":false,"given":"Amr Ali Mohamed Abdelgawwad","family":"El-Sehrawy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Y","family":"Alshahrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muzdalifa Mejbel","family":"Fedwi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subbulakshmi","family":"Ganesan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahraa Abbas","family":"Al-Khafaji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vimal","family":"Arora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8877-8025","authenticated-orcid":false,"given":"Amrita","family":"Pal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-8421-3630","authenticated-orcid":false,"given":"Priya Priyadarshini","family":"Nayak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8009-3291","authenticated-orcid":false,"given":"Sarvar","family":"Islomov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7105-1161","authenticated-orcid":false,"given":"Chou-Yi","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.seminoncol.2025.152454_bib0001","doi-asserted-by":"crossref","first-page":"127","DOI":"10.12788\/j.sder.2018.028","article-title":"Immunotherapy for melanoma","volume":"37","author":"Cuevas","year":"2018","journal-title":"Semin Cutan Med Surg"},{"key":"10.1016\/j.seminoncol.2025.152454_bib0002","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/9235638","article-title":"Immunotherapy in the treatment of metastatic melanoma: current knowledge and future directions","volume":"2020","author":"Ralli","year":"2020","journal-title":"J Immunol Res"},{"issue":"7559","key":"10.1016\/j.seminoncol.2025.152454_bib0003","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nature14404","article-title":"Melanoma-intrinsic \u03b2-catenin signalling prevents anti-tumour immunity","volume":"523","author":"Spranger","year":"2015","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.seminoncol.2025.152454_bib0004","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1038\/s41587-023-02060-8","article-title":"IL-10-expressing CAR T cells resist dysfunction and mediate durable clearance of solid tumors and metastases","volume":"42","author":"Zhao","year":"2024","journal-title":"Nat Biotechnol"},{"issue":"3","key":"10.1016\/j.seminoncol.2025.152454_bib0005","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.soc.2019.02.001","article-title":"Current immunotherapy practices in Melanoma","volume":"28","author":"Rothermel","year":"2019","journal-title":"Surg Oncol Clin N Am"},{"issue":"8049","key":"10.1016\/j.seminoncol.2025.152454_bib0006","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/s41586-024-08439-0","article-title":"Immune evasion through mitochondrial transfer in the tumour microenvironment","volume":"638","author":"Ikeda","year":"2025","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.seminoncol.2025.152454_bib0007","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.cell.2018.11.043","article-title":"Dysfunctional CD8 T cells form a proliferative, dynamically regulated compartment within Human melanoma","volume":"176","author":"Li","year":"2019","journal-title":"Cell"},{"issue":"10","key":"10.1016\/j.seminoncol.2025.152454_bib0008","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005020","article-title":"Blockades of effector T cell senescence and exhaustion synergistically enhance antitumor immunity and immunotherapy","volume":"10","author":"Liu","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"7","key":"10.1016\/j.seminoncol.2025.152454_bib0009","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1007\/s00105-013-2735-6","article-title":"Targeted therapies for melanoma","volume":"65","author":"Leiter","year":"2014","journal-title":"Hautarzt"},{"issue":"2","key":"10.1016\/j.seminoncol.2025.152454_bib0010","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.canrad.2018.05.006","article-title":"Treatment of patients with brain metastases from a melanoma","volume":"23","author":"Modesto","year":"2019","journal-title":"Cancer Radiother"},{"issue":"12","key":"10.1016\/j.seminoncol.2025.152454_bib0011","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1007\/s00105-012-2470-4","article-title":"Immunotherapy of melanomas","volume":"63","author":"Zimmer","year":"2012","journal-title":"Hautarzt"},{"issue":"1","key":"10.1016\/j.seminoncol.2025.152454_bib0012","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.annpat.2016.12.011","article-title":"Tissue biomarkers of response to anti-PD-1 immunotherapies in melanoma]","volume":"37","author":"Adam","year":"2017","journal-title":"Ann Pathol"},{"issue":"10","key":"10.1016\/j.seminoncol.2025.152454_bib0013","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1055\/s-2000-10682","article-title":"[Immunotherapy in malignant melanoma]","volume":"125","author":"Braathen","year":"2000","journal-title":"Zentralbl Chir"},{"issue":"7910","key":"10.1016\/j.seminoncol.2025.152454_bib0014","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1038\/s41586-022-04682-5","article-title":"Landscape of helper and regulatory antitumour CD4(+) T cells in melanoma","volume":"605","author":"Oliveira","year":"2022","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.seminoncol.2025.152454_bib0015","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1007\/s00105-008-1537-8","article-title":"[Immunization strategies for treating melanoma]","volume":"59","author":"Schultz","year":"2008","journal-title":"Hautarzt"},{"key":"10.1016\/j.seminoncol.2025.152454_bib0016","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.3389\/fimmu.2020.02105","article-title":"Tumor-infiltrating lymphocytes and their prognostic value in cutaneous melanoma","volume":"11","author":"Maibach","year":"2020","journal-title":"Front Immunol"},{"issue":"9","key":"10.1016\/j.seminoncol.2025.152454_bib0017","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1038\/s43018-024-00810-4","article-title":"A targetable type III immune response with increase of IL-17A expressing CD4(+) T\u2009cells is associated with immunotherapy-induced toxicity in melanoma","volume":"5","author":"Dimitriou","year":"2024","journal-title":"Nat Cancer"},{"issue":"7","key":"10.1016\/j.seminoncol.2025.152454_bib0018","doi-asserted-by":"crossref","DOI":"10.3390\/cells11071157","article-title":"Understanding molecular mechanisms of phenotype switching and crosstalk with TME to reveal new vulnerabilities of melanoma","volume":"11","author":"Najem","year":"2022","journal-title":"Cells"},{"issue":"2","key":"10.1016\/j.seminoncol.2025.152454_bib0019","first-page":"135","article-title":"Immunology of melanoma]","volume":"73","author":"Vanwijck","year":"1974","journal-title":"Acta Chir Belg"},{"issue":"10304","key":"10.1016\/j.seminoncol.2025.152454_bib0020","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/S0140-6736(21)01206-X","article-title":"Immune checkpoint inhibitors in melanoma","volume":"398","author":"Carlino","year":"2021","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.seminoncol.2025.152454_bib0021","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2021.1971015","article-title":"Neoadjuvant immune checkpoint inhibitors in high-risk stage III melanoma","volume":"18","author":"Ferraresi","year":"2022","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.seminoncol.2025.152454_bib0022","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102499","article-title":"Mechanisms of resistance to immune checkpoint inhibitors in melanoma: what we have to overcome?","volume":"113","author":"Ziogas","year":"2023","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"10.1016\/j.seminoncol.2025.152454_bib0023","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2021.1940676","article-title":"Anti-tumor efficacy of a combination therapy with PD-L1 targeted alpha therapy and adoptive cell transfer of PD-1 deficient melanoma-specific human T-lymphocytes","volume":"10","author":"Marotte","year":"2021","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.seminoncol.2025.152454_bib0024","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1178060","article-title":"Combining CSPG4-CAR and CD20-CCR for treatment of metastatic melanoma","volume":"14","author":"Teppert","year":"2023","journal-title":"Front Immunol"},{"issue":"17","key":"10.1016\/j.seminoncol.2025.152454_bib0025","doi-asserted-by":"crossref","first-page":"7622","DOI":"10.7150\/thno.43991","article-title":"Tandem CAR-T cells targeting CD70 and B7-H3 exhibit potent preclinical activity against multiple solid tumors","volume":"10","author":"Yang","year":"2020","journal-title":"Theranostics"},{"issue":"8","key":"10.1016\/j.seminoncol.2025.152454_bib0026","doi-asserted-by":"crossref","first-page":"3419","DOI":"10.21873\/anticanres.16517","article-title":"T cells expressing CAR equipped with extracellular domain of BTLA are effective against HVEM-over-expressing melanoma Cell lines","volume":"43","author":"Kim","year":"2023","journal-title":"Anticancer Res"},{"issue":"14","key":"10.1016\/j.seminoncol.2025.152454_bib0027","doi-asserted-by":"crossref","first-page":"3241","DOI":"10.1158\/1078-0432.CCR-14-3197","article-title":"Genetic engineering of T cells to target HERV-K, an ancient retrovirus on melanoma","volume":"21","author":"Krishnamurthy","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.seminoncol.2025.152454_bib0028","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/S0952-7915(00)00195-3","article-title":"Immunity against cancer: lessons learned from melanoma","volume":"13","author":"Houghton","year":"2001","journal-title":"Curr Opinion Immunol"},{"key":"10.1016\/j.seminoncol.2025.152454_bib0029","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.3389\/fimmu.2019.01856","article-title":"Mutation-derived neoantigens for cancer immunotherapy","volume":"10","author":"Castle","year":"2019","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.seminoncol.2025.152454_bib0030","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1158\/1078-0432.CCR-05-1544","article-title":"Tumor antigen expression in melanoma varies according to antigen and stage","volume":"12","author":"Barrow","year":"2006","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.seminoncol.2025.152454_bib0031","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2024.2303799","article-title":"Relevance of mutation-derived neoantigens and non-classical antigens for anticancer therapies","volume":"20","author":"Aparicio","year":"2024","journal-title":"Human Vaccines Immunotherapeutics"},{"issue":"6","key":"10.1016\/j.seminoncol.2025.152454_bib0032","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1111\/pcmr.12807","article-title":"C57BL\/6 congenic mouse NRASQ61K melanoma cell lines are highly sensitive to the combination of Mek and Akt inhibitors in vitro and in vivo","volume":"32","author":"Petit","year":"2019","journal-title":"Pigment Cell Melanoma Res"},{"issue":"20","key":"10.1016\/j.seminoncol.2025.152454_bib0033","doi-asserted-by":"crossref","first-page":"3180","DOI":"10.1038\/sj.onc.1206462","article-title":"Immunity to melanoma: unraveling the relation of tumor immunity and autoimmunity","volume":"22","author":"Ramirez-Montagut","year":"2003","journal-title":"Oncogene"},{"issue":"450","key":"10.1016\/j.seminoncol.2025.152454_bib0034","doi-asserted-by":"crossref","first-page":"eaar3342","DOI":"10.1126\/scitranslmed.aar3342","article-title":"MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma","volume":"10","author":"Rodig","year":"2018","journal-title":"Sci Transl Med"},{"issue":"4","key":"10.1016\/j.seminoncol.2025.152454_bib0035","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/s41568-022-00442-9","article-title":"Mechanisms of immune activation and regulation: lessons from melanoma","volume":"22","author":"Kalaora","year":"2022","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"10.1016\/j.seminoncol.2025.152454_bib0036","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/imm.13114","article-title":"Cancer immune escape: MHC expression in primary tumours versus metastases","volume":"158","author":"Garrido","year":"2019","journal-title":"Immunology"},{"issue":"1","key":"10.1016\/j.seminoncol.2025.152454_bib0037","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1034\/j.1600-065X.2002.18809.x","article-title":"Immunity to cancer: attack and escape in T lymphocyte\u2013tumor cell interaction","volume":"188","author":"Rivoltini","year":"2002","journal-title":"Immunological Rev"},{"issue":"7739","key":"10.1016\/j.seminoncol.2025.152454_bib0038","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/s41586-018-0812-9","article-title":"Tissue-resident memory CD8+ T cells promote melanoma\u2013immune equilibrium in skin","volume":"565","author":"Park","year":"2019","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.seminoncol.2025.152454_bib0039","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1038\/nm.2856","article-title":"Robust tumor immunity to melanoma mediated by interleukin-9\u2013producing T cells","volume":"18","author":"Purwar","year":"2012","journal-title":"Nat Med"},{"issue":"12","key":"10.1016\/j.seminoncol.2025.152454_bib0040","first-page":"4296","article-title":"Natural T cell immunity against cancer","volume":"9","author":"Nagorsen","year":"2003","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.seminoncol.2025.152454_bib0041","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1146\/annurev.immunol.24.021605.090733","article-title":"Bruggen Pvd: human T cell responses against melanoma","volume":"24","author":"Boon","year":"2006","journal-title":"Annu Rev Immunol"},{"issue":"2","key":"10.1016\/j.seminoncol.2025.152454_bib0042","doi-asserted-by":"crossref","DOI":"10.1172\/JCI150535","article-title":"Neoantigen-reactive CD8+ T cells affect clinical outcome of adoptive cell therapy with tumor-infiltrating lymphocytes in melanoma","volume":"132","author":"Kristensen","year":"2022","journal-title":"J Clin Invest"},{"issue":"7953","key":"10.1016\/j.seminoncol.2025.152454_bib0043","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1038\/s41586-023-05787-1","article-title":"Neoantigen-targeted CD8(+) T cell responses with PD-1 blockade therapy","volume":"615","author":"Puig-Saus","year":"2023","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.seminoncol.2025.152454_bib0044","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1038\/s41591-024-03418-4","article-title":"Personalized, autologous neoantigen-specific T cell therapy in metastatic melanoma: a phase 1 trial","volume":"31","author":"Borgers","year":"2025","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.seminoncol.2025.152454_bib0045","doi-asserted-by":"crossref","first-page":"3188","DOI":"10.1038\/s41467-023-38946-z","article-title":"Neoantigen-specific CD8 T cells with high structural avidity preferentially reside in and eliminate tumors","volume":"14","author":"Schmidt","year":"2023","journal-title":"Nat Commun"},{"issue":"4","key":"10.1016\/j.seminoncol.2025.152454_bib0046","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.ccell.2022.03.006","article-title":"Neoantigen-specific CD4(+) T cells in human melanoma have diverse differentiation states and correlate with CD8(+) T cell, macrophage, and B cell function","volume":"40","author":"Veatch","year":"2022","journal-title":"Cancer Cell"},{"issue":"7","key":"10.1016\/j.seminoncol.2025.152454_bib0047","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.111639","article-title":"CD8(+) T cell metabolic rewiring defined by scRNA-seq identifies a critical role of ASNS expression dynamics in T cell differentiation","volume":"41","author":"Fern\u00e1ndez-Garc\u00eda","year":"2022","journal-title":"Cell Rep"},{"issue":"3","key":"10.1016\/j.seminoncol.2025.152454_bib0048","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/s42255-025-01233-w","article-title":"A functional single-cell metabolic survey identifies Elovl1 as a target to enhance CD8(+) T cell fitness in solid tumours","volume":"7","author":"Pretto","year":"2025","journal-title":"Nat Metab"},{"issue":"8","key":"10.1016\/j.seminoncol.2025.152454_bib0049","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/s41419-023-06068-5","article-title":"Clinical-mediated discovery of pyroptosis in CD8(+) T cell and NK cell reveals melanoma heterogeneity by single-cell and bulk sequence","volume":"14","author":"Zhang","year":"2023","journal-title":"Cell Death Dis"},{"issue":"12","key":"10.1016\/j.seminoncol.2025.152454_bib0050","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1080\/1744666X.2022.2141228","article-title":"IRF1 expression might be a biomarker of CD8+ T cell infiltration in cutaneous melanoma","volume":"18","author":"Zhou","year":"2022","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.seminoncol.2025.152454_bib0051","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.659444","article-title":"Development and validation of a CD8+ T cell infiltration-related signature for melanoma patients","volume":"12","author":"Yuan","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.seminoncol.2025.152454_bib0052","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1039565","article-title":"A CD8(+) T cell-associated immune gene panel for prediction of the prognosis and immunotherapeutic effect of melanoma","volume":"13","author":"Sun","year":"2022","journal-title":"Front Immunol"},{"issue":"32","key":"10.1016\/j.seminoncol.2025.152454_bib0053","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000038924","article-title":"Bioinformatics analysis of the tumor microenvironment in melanoma - constructing a prognostic model based on CD8+ T cell-related genes: an observational study","volume":"103","author":"He","year":"2024","journal-title":"Medicine"},{"issue":"91","key":"10.1016\/j.seminoncol.2025.152454_bib0054","doi-asserted-by":"crossref","first-page":"eadi9517","DOI":"10.1126\/sciimmunol.adi9517","article-title":"CD4(+) T cell immunity against cutaneous melanoma encompasses multifaceted MHC II-dependent responses","volume":"9","author":"Bawden","year":"2024","journal-title":"Sci Immunol"},{"key":"10.1016\/j.seminoncol.2025.152454_bib0055","doi-asserted-by":"crossref","unstructured":"Liu Q, Wang L, Lin H, et al.: Tumor-specific CD4(+) T cells restrain established metastatic melanoma by developing into cytotoxic CD4(-) T cells. Front Immunol 2022, 13:875718.","DOI":"10.3389\/fimmu.2022.875718"},{"issue":"10","key":"10.1016\/j.seminoncol.2025.152454_bib0056","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007288","article-title":"Neoantigen-specific CD4(+) tumor-infiltrating lymphocytes are potent effectors identified within adoptive cell therapy products for metastatic melanoma patients","volume":"11","author":"Hall","year":"2023","journal-title":"J Immunother Cancer"},{"issue":"12","key":"10.1016\/j.seminoncol.2025.152454_bib0057","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007239","article-title":"Differential requirements for CD4+ T cells in the efficacy of the anti-PD-1+LAG-3 and anti-PD-1+CTLA-4 combinations in melanoma flank and brain metastasis models","volume":"11","author":"Phadke","year":"2023","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10.1016\/j.seminoncol.2025.152454_bib0058","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s12865-022-00509-0","article-title":"Interleukin-7 regulates CD127 expression and promotes CD8(+) T cell activity in patients with primary cutaneous melanoma","volume":"23","author":"He","year":"2022","journal-title":"BMC Immunol"},{"key":"10.1016\/j.seminoncol.2025.152454_bib0059","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/5416843","article-title":"FOXP3 in melanoma with regression: between tumoral expression and regulatory T cell upregulation","volume":"2020","author":"Cioplea","year":"2020","journal-title":"J Immunol Res"},{"issue":"6","key":"10.1016\/j.seminoncol.2025.152454_bib0060","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.ccell.2024.05.013","article-title":"Interruption of the intratumor CD8(+) T cell:treg crosstalk improves the efficacy of PD-1 immunotherapy","volume":"42","author":"Geels","year":"2024","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.seminoncol.2025.152454_bib0061","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009435","article-title":"Anti-PD-1 amplifies costimulation in melanoma-infiltrating T(h)1-like Foxp3(+) regulatory T cells to alleviate local immunosuppression","volume":"13","author":"Attias","year":"2025","journal-title":"J Immunother Cancer"},{"issue":"2","key":"10.1016\/j.seminoncol.2025.152454_bib0062","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/s00018-020-03517-8","article-title":"Melanoma-associated fibroblasts impair CD8+\u2009T cell function and modify expression of immune checkpoint regulators via increased arginase activity","volume":"78","author":"\u00c9rsek","year":"2021","journal-title":"Cell Mol Life Sci"},{"issue":"16","key":"10.1016\/j.seminoncol.2025.152454_bib0063","doi-asserted-by":"crossref","first-page":"4355","DOI":"10.1016\/j.cell.2024.07.016","article-title":"LAG-3 and PD-1 synergize on CD8(+) T cells to drive T cell exhaustion and hinder autocrine IFN-\u03b3-dependent anti-tumor immunity","volume":"187","author":"Andrews","year":"2024","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.seminoncol.2025.152454_bib0064","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.ccell.2020.09.001","article-title":"The PD-1\/PD-L1-checkpoint restrains T cell immunity in tumor-draining lymph nodes","volume":"38","author":"Dammeijer","year":"2020","journal-title":"Cancer Cell"},{"issue":"6","key":"10.1016\/j.seminoncol.2025.152454_bib0065","doi-asserted-by":"crossref","DOI":"10.1172\/JCI164809","article-title":"Single-cell characterization of anti-LAG-3 and anti-PD-1 combination treatment in patients with melanoma","volume":"133","author":"Huuhtanen","year":"2023","journal-title":"J Clin Invest"},{"issue":"6","key":"10.1016\/j.seminoncol.2025.152454_bib0066","doi-asserted-by":"crossref","DOI":"10.3390\/cells12060856","article-title":"Circulating melanoma cell numbers correlate with TIGIT-positive cytotoxic T cell counts in advanced-stage melanoma patients","volume":"12","author":"Kami\u0144ska","year":"2023","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.seminoncol.2025.152454_bib0067","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2024.2376782","article-title":"Differential impact of genetic deletion of TIGIT or PD-1 on melanoma-specific T-lymphocytes","volume":"13","author":"Cadiou","year":"2024","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.seminoncol.2025.152454_bib0068","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1362152","article-title":"The effect of gD-derived peptides on T cell immune response mediated by BTLA-HVEM protein complex in melanoma patients","volume":"15","author":"Wojciechowicz","year":"2024","journal-title":"Front Immunol"},{"issue":"18","key":"10.1016\/j.seminoncol.2025.152454_bib0069","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241813742","article-title":"Enhancement of radiation therapy through blockade of the immune checkpoint, V-domain ig suppressor of T cell activation (VISTA), in melanoma and adenocarcinoma murine models","volume":"24","author":"Duval","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"3","key":"10.1016\/j.seminoncol.2025.152454_bib0070","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.molmed.2014.12.007","article-title":"Molecular drivers of cellular metabolic reprogramming in melanoma","volume":"21","author":"Abildgaard","year":"2015","journal-title":"Trends Molecular Med"},{"issue":"12","key":"10.1016\/j.seminoncol.2025.152454_bib0071","doi-asserted-by":"crossref","first-page":"4193","DOI":"10.3390\/jcm14124193","article-title":"Nutrition and diet patterns as key modulators of metabolic reprogramming in Melanoma Immunotherapy","volume":"14","author":"Grafanaki","year":"2025","journal-title":"J Clin Med"},{"issue":"11","key":"10.1016\/j.seminoncol.2025.152454_bib0072","doi-asserted-by":"crossref","first-page":"3147","DOI":"10.3390\/cancers12113147","article-title":"Lipid metabolic reprogramming: role in melanoma progression and therapeutic perspectives","volume":"12","author":"Pellerin","year":"2020","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.seminoncol.2025.152454_bib0073","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s40169-016-0110-9","article-title":"Clinical significance of T cell metabolic reprogramming in cancer","volume":"5","author":"Herbel","year":"2016","journal-title":"Clin Transl Med"},{"issue":"2","key":"10.1016\/j.seminoncol.2025.152454_bib0074","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/imm.12777","article-title":"Metabolic reprogramming in the tumour microenvironment: a hallmark shared by cancer cells and T lymphocytes","volume":"152","author":"Allison","year":"2017","journal-title":"Immunology"},{"issue":"2","key":"10.1016\/j.seminoncol.2025.152454_bib0075","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/onc.2016.198","article-title":"Metabolic rewiring in melanoma","volume":"36","author":"Ratnikov","year":"2017","journal-title":"Oncogene"},{"issue":"717","key":"10.1016\/j.seminoncol.2025.152454_bib0076","doi-asserted-by":"crossref","first-page":"eadd2712","DOI":"10.1126\/scitranslmed.add2712","article-title":"Lactate oxidase nanocapsules boost T cell immunity and efficacy of cancer immunotherapy","volume":"15","author":"Cao","year":"2023","journal-title":"Sci Transl Med"},{"issue":"1","key":"10.1016\/j.seminoncol.2025.152454_bib0077","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20202084","article-title":"A high OXPHOS CD8 T cell subset is predictive of immunotherapy resistance in melanoma patients","volume":"219","author":"Li","year":"2022","journal-title":"J Exp Med"},{"issue":"1","key":"10.1016\/j.seminoncol.2025.152454_bib0078","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1186\/s12935-025-03781-3","article-title":"Ghorbaninezhad F: a new era in melanoma immunotherapy: focus on DCs metabolic reprogramming","volume":"25","author":"Nour","year":"2025","journal-title":"Cancer Cell Int"},{"issue":"1","key":"10.1016\/j.seminoncol.2025.152454_bib0079","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.cmet.2022.12.003","article-title":"Immunoediting instructs tumor metabolic reprogramming to support immune evasion","volume":"35","author":"Tsai","year":"2023","journal-title":"Cell metabolism"},{"issue":"21","key":"10.1016\/j.seminoncol.2025.152454_bib0080","doi-asserted-by":"crossref","DOI":"10.1172\/JCI167951","article-title":"Targeting TREM1 augments antitumor T cell immunity by inhibiting myeloid-derived suppressor cells and restraining anti-PD-1 resistance","volume":"133","author":"Ajith","year":"2023","journal-title":"J Clin Invest"},{"key":"10.1016\/j.seminoncol.2025.152454_bib0081","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.932298","article-title":"TIE-2 signaling activation by Angiopoietin 2 on myeloid-derived suppressor cells promotes melanoma-specific T-cell inhibition","volume":"13","author":"Marguier","year":"2022","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.seminoncol.2025.152454_bib0082","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1016\/j.ymthe.2022.02.005","article-title":"Immunodepletion of MDSC by AMV564, a novel bivalent, bispecific CD33\/CD3 T cell engager, ex vivo in MDS and melanoma","volume":"30","author":"Cheng","year":"2022","journal-title":"Mol Ther"},{"issue":"3","key":"10.1016\/j.seminoncol.2025.152454_bib0083","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1002\/path.6083","article-title":"Fusion with type 2 macrophages induces melanoma cell heterogeneity that potentiates immunological escape from cytotoxic T lymphocytes","volume":"260","author":"Minowa","year":"2023","journal-title":"J Pathol"},{"key":"10.1016\/j.seminoncol.2025.152454_bib0084","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.768753","article-title":"T cells and CDDO-me attenuate immunosuppressive activation of Human melanoma-conditioned macrophages","volume":"13","author":"Torres","year":"2022","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.seminoncol.2025.152454_bib0085","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2021.1950953","article-title":"Hypoxia increases melanoma-associated fibroblasts immunosuppressive potential and inhibitory effect on T cell-mediated cytotoxicity","volume":"10","author":"Ziani","year":"2021","journal-title":"Oncoimmunology"},{"issue":"5","key":"10.1016\/j.seminoncol.2025.152454_bib0086","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-004533","article-title":"Activin-A impairs CD8 T cell-mediated immunity and immune checkpoint therapy response in melanoma","volume":"10","author":"Pinjusic","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10.1016\/j.seminoncol.2025.152454_bib0087","doi-asserted-by":"crossref","first-page":"5740","DOI":"10.1038\/s41467-023-41101-3","article-title":"Activation of melanocortin-1 receptor signaling in melanoma cells impairs T cell infiltration to dampen antitumor immunity","volume":"14","author":"Cui","year":"2023","journal-title":"Nat Commun"},{"issue":"4","key":"10.1016\/j.seminoncol.2025.152454_bib0088","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004150","article-title":"Glucocorticoid activation by HSD11B1 limits T cell-driven interferon signaling and response to PD-1 blockade in melanoma","volume":"11","author":"Martins Nascentes Melo","year":"2023","journal-title":"J Immunother Cancer"},{"issue":"12","key":"10.1016\/j.seminoncol.2025.152454_bib0089","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1158\/0008-5472.CAN-22-2838","article-title":"Angiopoietin-2-dependent spatial vascular destabilization promotes T-cell exclusion and limits immunotherapy in melanoma","volume":"83","author":"Park","year":"2023","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.seminoncol.2025.152454_bib0090","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/s12943-023-01833-8","article-title":"Unleashing T cell anti-tumor immunity: new potential for 5-nonloxytryptamine as an agent mediating MHC-I upregulation in tumors","volume":"22","author":"Stachura","year":"2023","journal-title":"Mol Cancer"},{"issue":"1","key":"10.1016\/j.seminoncol.2025.152454_bib0091","doi-asserted-by":"crossref","first-page":"3014","DOI":"10.1038\/s41467-024-47301-9","article-title":"Stroma-infiltrating T cell spatiotypes define immunotherapy outcomes in adolescent and young adult patients with melanoma","volume":"15","author":"Bai","year":"2024","journal-title":"Nat Commun"},{"issue":"3","key":"10.1016\/j.seminoncol.2025.152454_bib0092","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001962","article-title":"T cell infiltration on local CpG-B delivery in early-stage melanoma is predominantly related to CLEC9A(+)CD141(+) cDC1 and CD14(+) antigen-presenting cell recruitment","volume":"9","author":"Koster","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.seminoncol.2025.152454_bib0093","article-title":"Single-cell transcriptomic analysis reveals the crosstalk propensity between the tumor intermediate State and the CD8+ T exhausted State to be associated with clinical benefits in melanoma","volume":"13","author":"Zhu","year":"2022","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.seminoncol.2025.152454_bib0094","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1093\/bjd\/ljae433","article-title":"Spatial proteomics reveals sirtuin 1 to be a determinant of T-cell infiltration in human melanoma","volume":"192","author":"Placke","year":"2025","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.seminoncol.2025.152454_bib0095","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1080\/14712598.2022.2038132","article-title":"Immune checkpoint inhibitors for the treatment of melanoma","volume":"22","author":"Sabbatino","year":"2022","journal-title":"Expert Opin Biol Ther"},{"issue":"1","key":"10.1016\/j.seminoncol.2025.152454_bib0096","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2024.2372118","article-title":"Modulation of blood T cell polyfunctionality and HVEM\/BTLA expression are critical determinants of clinical outcome in anti-PD1-treated metastatic melanoma patients","volume":"13","author":"Dalle","year":"2024","journal-title":"Oncoimmunology"},{"issue":"2","key":"10.1016\/j.seminoncol.2025.152454_bib0097","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/s41435-021-00138-4","article-title":"Early memory differentiation and cell death resistance in T cells predicts melanoma response to sequential anti-CTLA4 and anti-PD1 immunotherapy","volume":"22","author":"Vanmeerbeek","year":"2021","journal-title":"Genes Immun"},{"issue":"8","key":"10.1016\/j.seminoncol.2025.152454_bib0098","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1158\/0008-5472.CAN-23-3918","article-title":"Single-cell analyses reveal a functionally heterogeneous exhausted CD8+ T-cell subpopulation that is correlated with response to checkpoint therapy in melanoma","volume":"85","author":"Mahuron","year":"2025","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.seminoncol.2025.152454_bib0099","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1111\/cas.16073","article-title":"Interleukin-4 induced 1-mediated resistance to an immune checkpoint inhibitor through suppression of CD8(+) T cell infiltration in melanoma","volume":"115","author":"Hirose","year":"2024","journal-title":"Cancer Sci"},{"issue":"15","key":"10.1016\/j.seminoncol.2025.152454_bib0100","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2013598118","article-title":"Epigenetic reprogramming of tumor cell-intrinsic STING function sculpts antigenicity and T cell recognition of melanoma","volume":"118","author":"Falahat","year":"2021","journal-title":"Proc Natl Acad Sci USA"},{"issue":"8","key":"10.1016\/j.seminoncol.2025.152454_bib0101","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0134678","article-title":"Prognostic significance of nuclear phospho-ATM expression in Melanoma","volume":"10","author":"Bhandaru","year":"2015","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.seminoncol.2025.152454_bib0102","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1038\/s41436-021-01240-8","article-title":"Germline ATM variants predispose to melanoma: a joint analysis across the GenoMEL and MelaNostrum consortia","volume":"23","author":"Dalmasso","year":"2021","journal-title":"Genet Med"},{"issue":"Suppl 3","key":"10.1016\/j.seminoncol.2025.152454_bib0103","doi-asserted-by":"crossref","first-page":"S118","DOI":"10.21037\/atm.2019.05.62","article-title":"Immunotherapy for mucosal melanoma","volume":"7","author":"Yentz","year":"2019","journal-title":"Ann Transl Med"},{"issue":"9","key":"10.1016\/j.seminoncol.2025.152454_bib0104","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007474","article-title":"ATM inhibition augments type I interferon response and antitumor T-cell immunity when combined with radiation therapy in murine tumor models","volume":"11","author":"Jin","year":"2023","journal-title":"J Immunother Cancer"},{"issue":"4","key":"10.1016\/j.seminoncol.2025.152454_bib0105","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.ijrobp.2020.10.025","article-title":"Melanoma cell intrinsic GABA(A) receptor enhancement potentiates radiation and immune checkpoint inhibitor response by promoting direct and T cell-mediated antitumor activity","volume":"109","author":"Pomeranz Krummel","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.seminoncol.2025.152454_bib0106","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1279387","article-title":"A phase I oncolytic virus trial with vesicular stomatitis virus expressing human interferon beta and tyrosinase related protein 1 administered intratumorally and intravenously in uveal melanoma: safety, efficacy, and T cell responses","volume":"14","author":"Smith","year":"2023","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.seminoncol.2025.152454_bib0107","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006374","article-title":"OncoVEX(mGM-CSF)expands tumor antigen-specific CD8+ T-cell response in preclinical models","volume":"11","author":"Estrada","year":"2023","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10.1016\/j.seminoncol.2025.152454_bib0108","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010683","article-title":"Combined PARP14 inhibition and PD-1 blockade promotes cytotoxic T cell quiescence and modulates macrophage polarization in relapsed melanoma","volume":"13","author":"Leshem","year":"2025","journal-title":"J Immunother Cancer"},{"issue":"6641","key":"10.1016\/j.seminoncol.2025.152454_bib0109","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1126\/science.abp9563","article-title":"Engineered skin bacteria induce antitumor T cell responses against melanoma","volume":"380","author":"Chen","year":"2023","journal-title":"Science"},{"key":"10.1016\/j.seminoncol.2025.152454_bib0110","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.3389\/fimmu.2020.01147","article-title":"Evaluation of T-cell responses against shared melanoma associated antigens and predicted neoantigens in cutaneous melanoma patients treated with the CSF-470 allogeneic Cell Vaccine Plus BCG and GM-CSF","volume":"11","author":"Podaza","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.seminoncol.2025.152454_bib0111","article-title":"VACCIMEL, an allogeneic melanoma vaccine, efficiently triggers T cell immune responses against neoantigens and alloantigens, as well as against tumor-associated antigens","volume":"15","author":"Carri","year":"2024","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.seminoncol.2025.152454_bib0112","doi-asserted-by":"crossref","first-page":"665","DOI":"10.4161\/cbt.28555","article-title":"Osella-Abate S: melanoma immunotherapy","volume":"15","author":"Sanlorenzo","year":"2014","journal-title":"Cancer Biol Ther"},{"issue":"8","key":"10.1016\/j.seminoncol.2025.152454_bib0113","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1097\/CJI.0b013e31826e8f5f","article-title":"Efficacy of adoptive cell transfer of tumor-infiltrating lymphocytes after lymphopenia induction for metastatic melanoma","volume":"35","author":"Pilon-Thomas","year":"2012","journal-title":"J Immunother"},{"issue":"2","key":"10.1016\/j.seminoncol.2025.152454_bib0114","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1158\/2326-6066.CIR-16-0288","article-title":"Long-term survival and clinical benefit from adoptive T-cell transfer in stage IV melanoma patients is determined by a four-parameter tumor immune signature","volume":"5","author":"Melief","year":"2017","journal-title":"Cancer Immunol Res"},{"issue":"8","key":"10.1016\/j.seminoncol.2025.152454_bib0115","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1097\/CJI.0b013e31826e8f5f","article-title":"Efficacy of adoptive cell transfer of tumor-infiltrating lymphocytes after lymphopenia induction for metastatic melanoma","volume":"35","author":"Pilon-Thomas","year":"2012","journal-title":"J Immunother"},{"issue":"10","key":"10.1016\/j.seminoncol.2025.152454_bib0116","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1007\/s00262-014-1575-2","article-title":"A phase I clinical trial combining dendritic cell vaccination with adoptive T cell transfer in patients with stage IV melanoma","volume":"63","author":"Poschke","year":"2014","journal-title":"Cancer Immunol Immunother"},{"issue":"13","key":"10.1016\/j.seminoncol.2025.152454_bib0117","doi-asserted-by":"crossref","first-page":"4550","DOI":"10.1158\/1078-0432.CCR-11-0116","article-title":"Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy","volume":"17","author":"Rosenberg","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.seminoncol.2025.152454_bib0118","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002449","article-title":"Randomized phase II trial of lymphodepletion plus adoptive cell transfer of tumor-infiltrating lymphocytes, with or without dendritic cell vaccination, in patients with metastatic melanoma","volume":"9","author":"Saberian","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"12","key":"10.1016\/j.seminoncol.2025.152454_bib0119","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1111\/exd.13792","article-title":"CAR-T cell therapy in melanoma: a future success story?","volume":"27","author":"Simon","year":"2018","journal-title":"Expl Dermatol"},{"issue":"11","key":"10.1016\/j.seminoncol.2025.152454_bib0120","doi-asserted-by":"crossref","first-page":"10627","DOI":"10.1007\/s11033-022-07633-5","article-title":"Opportunities and obstacles for the melanoma immunotherapy using T cell and chimeric antigen receptor T (CAR-T) applications: a literature review","volume":"49","author":"Bahmanyar","year":"2022","journal-title":"Molecular Biol Rep"},{"issue":"6","key":"10.1016\/j.seminoncol.2025.152454_bib0121","doi-asserted-by":"crossref","first-page":"e406","DOI":"10.1093\/oncolo\/oyad078","article-title":"Efficacy of T-cell receptor-based adoptive cell therapy in cutaneous melanoma: a meta-analysis","volume":"28","author":"Yarza","year":"2023","journal-title":"Oncologist"},{"issue":"10","key":"10.1016\/j.seminoncol.2025.152454_bib0122","doi-asserted-by":"crossref","first-page":"5315","DOI":"10.4049\/jimmunol.1302074","article-title":"TCRs genetically linked to CD28 and CD3\u03b5 do not mispair with endogenous TCR chains and mediate enhanced T cell persistence and anti-melanoma activity","volume":"193","author":"Govers","year":"2014","journal-title":"J Immunol"},{"issue":"9","key":"10.1016\/j.seminoncol.2025.152454_bib0123","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1158\/1078-0432.CCR-13-3017","article-title":"Adoptive transfer of MART-1 T-cell receptor transgenic lymphocytes and dendritic cell vaccination in patients with metastatic melanoma","volume":"20","author":"Chodon","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.seminoncol.2025.152454_bib0124","doi-asserted-by":"crossref","first-page":"867","DOI":"10.2340\/1651-226X.2024.40495","article-title":"NIVO-TIL: combination anti-PD-1 therapy and adoptive T-cell transfer in untreated metastatic melanoma: an exploratory open-label phase I trial","volume":"63","author":"L'Orphelin","year":"2024","journal-title":"Acta Oncol"},{"issue":"14","key":"10.1016\/j.seminoncol.2025.152454_bib0125","doi-asserted-by":"crossref","first-page":"3042","DOI":"10.1158\/1078-0432.CCR-21-4499","article-title":"Neoantigen identification and response to adoptive cell transfer in Anti-PD-1 na\u00efve and experienced patients with metastatic melanoma","volume":"28","author":"Levi","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.seminoncol.2025.152454_bib0126","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1093\/oncolo\/oyae136","article-title":"Lifileucel: FDA-approved T-cell therapy for melanoma","volume":"29","author":"Kwong","year":"2024","journal-title":"Oncologist"},{"issue":"5","key":"10.1016\/j.seminoncol.2025.152454_bib0127","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1097\/CJI.0000000000000223","article-title":"Outcomes of adoptive cell transfer with tumor-infiltrating lymphocytes for metastatic melanoma patients with and without brain metastases","volume":"41","author":"Mehta","year":"2018","journal-title":"J Immunother"},{"issue":"2","key":"10.1016\/j.seminoncol.2025.152454_bib0128","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000848","article-title":"Tumor infiltrating lymphocytes (TIL) therapy in metastatic melanoma: boosting of neoantigen-specific T cell reactivity and long-term follow-up","volume":"8","author":"van den Berg","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"10","key":"10.1016\/j.seminoncol.2025.152454_bib0129","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1016\/j.immuni.2024.08.014","article-title":"Tumor-reactive T cell clonotype dynamics underlying clinical response to TIL therapy in melanoma","volume":"57","author":"Chiffelle","year":"2024","journal-title":"Immunity"},{"issue":"23","key":"10.1016\/j.seminoncol.2025.152454_bib0130","doi-asserted-by":"crossref","DOI":"10.3390\/cells11233894","article-title":"Pro- and anti-tumoral factors involved in total body irradiation and interleukin-2 conditioning in adoptive T cell therapy of melanoma-bearing Rag1 knock-out mice","volume":"11","author":"Kim","year":"2022","journal-title":"Cells"},{"issue":"3","key":"10.1016\/j.seminoncol.2025.152454_bib0131","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.immuni.2020.07.007","article-title":"Adoptive T cell therapy targeting different gene products reveals diverse and context-dependent immune evasion in melanoma","volume":"53","author":"Effern","year":"2020","journal-title":"Immunity"},{"issue":"10","key":"10.1016\/j.seminoncol.2025.152454_bib0132","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1007\/s00262-021-02961-0","article-title":"Phase I\/II clinical trial of adoptive cell transfer of sorted specific T cells for metastatic melanoma patients","volume":"70","author":"Dr\u00e9no","year":"2021","journal-title":"Cancer Immunol Immunother"},{"issue":"8_Supplement_1","key":"10.1016\/j.seminoncol.2025.152454_bib0133","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1158\/1538-7445.AM2025-863","article-title":"A novel SIRPA based FiCAR T cells therapy targeting TYRP1 to treat melanoma patients","volume":"85","author":"Paavilainen","year":"2025","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.seminoncol.2025.152454_bib0134","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1038\/s41467-024-45221-2","article-title":"CAR-T cell therapy targeting surface expression of TYRP1 to treat cutaneous and rare melanoma subtypes","volume":"15","author":"Jilani","year":"2024","journal-title":"Nat Commun"},{"issue":"14","key":"10.1016\/j.seminoncol.2025.152454_bib0135","first-page":"5214","article-title":"Consistent antibody response against ganglioside GD2 induced in patients with melanoma by a GD2 lactone-keyhole limpet hemocyanin conjugate vaccine plus immunological adjuvant QS-21","volume":"9","author":"Ragupathi","year":"2003","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.seminoncol.2025.152454_bib0136","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-017-0548-2","article-title":"Anti-GD2\/4-1BB chimeric antigen receptor T cell therapy for the treatment of Chinese melanoma patients","volume":"11","author":"Yu","year":"2018","journal-title":"J Hematol Oncol"},{"issue":"1","key":"10.1016\/j.seminoncol.2025.152454_bib0137","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1097\/CJI.0000000000000061","article-title":"BRAF and MEK inhibition variably affect GD2-specific chimeric antigen receptor (CAR) T-cell function in vitro","volume":"38","author":"Gargett","year":"2015","journal-title":"J Immunother"},{"issue":"5","key":"10.1016\/j.seminoncol.2025.152454_bib0138","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1158\/0008-5472.CAN-18-3158","article-title":"HER2 CAR-T cells eradicate uveal melanoma and T-cell therapy-resistant Human melanoma in IL2 transgenic NOD\/SCID IL2 receptor knockout mice","volume":"79","author":"Forsberg","year":"2019","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.seminoncol.2025.152454_bib0139","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s00262-014-1648-2","article-title":"DNAM-1-based chimeric antigen receptors enhance T cell effector function and exhibit in vivo efficacy against melanoma","volume":"64","author":"Wu","year":"2015","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.seminoncol.2025.152454_bib0140","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1178060","article-title":"Combining CSPG4-CAR and CD20-CCR for treatment of metastatic melanoma","volume":"14","author":"Teppert","year":"2023","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.seminoncol.2025.152454_bib0141","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1186\/s12967-025-06365-x","article-title":"MUC18-Directed chimeric antigen receptor T cells for the treatment of mucosal melanoma","volume":"23","author":"Zhang","year":"2025","journal-title":"J Transl Med"},{"issue":"15","key":"10.1016\/j.seminoncol.2025.152454_bib0142","doi-asserted-by":"crossref","first-page":"3243","DOI":"10.1158\/1078-0432.CCR-24-0071","article-title":"Chimeric antigen receptor T cell with an inducible caspase-9 suicide gene eradicates uveal melanoma liver metastases via B7-H3 targeting","volume":"30","author":"Ventin","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"13","key":"10.1016\/j.seminoncol.2025.152454_bib0143","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1016\/j.celrep.2017.09.002","article-title":"Augmentation of antitumor immunity by human and mouse CAR T cells secreting IL-18","volume":"20","author":"Hu","year":"2017","journal-title":"Cell Rep"},{"issue":"14","key":"10.1016\/j.seminoncol.2025.152454_bib0144","article-title":"Improved efficacy of triple-negative breast cancer immunotherapy via hydrogel-based Co-delivery of CAR-T cells and mitophagy agonist","volume":"12","author":"Li","year":"2025","journal-title":"Adv Sci"},{"key":"10.1016\/j.seminoncol.2025.152454_bib0145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41417-025-00931-7","article-title":"Barriers and solutions for CAR-T therapy in solid tumors","volume":"32","author":"Tu","year":"2025","journal-title":"Cancer Gene Therapy"},{"key":"10.1016\/j.seminoncol.2025.152454_bib0146","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2022.121872","article-title":"Injectable and photocurable CAR-T cell formulation enhances the anti-tumor activity to melanoma in mice","volume":"291","author":"Zhou","year":"2022","journal-title":"Biomaterials"},{"issue":"5","key":"10.1016\/j.seminoncol.2025.152454_bib0147","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1158\/2767-9764.CRC-22-0486","article-title":"Phase I trial of autologous RNA-electroporated cMET-directed CAR T cells administered intravenously in patients with melanoma and breast carcinoma","volume":"3","author":"Shah","year":"2023","journal-title":"Cancer Res Commun"},{"issue":"5","key":"10.1016\/j.seminoncol.2025.152454_bib0148","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008659","article-title":"Safety and biological outcomes following a phase 1 trial of GD2-specific CAR-T cells in patients with GD2-positive metastatic melanoma and other solid cancers","volume":"12","author":"Gargett","year":"2024","journal-title":"J Immunother Cancer"},{"issue":"3","key":"10.1016\/j.seminoncol.2025.152454_bib0149","article-title":"TYRP1 directed CAR T cells control tumor progression in preclinical melanoma models","volume":"32","author":"Hackett","year":"2024","journal-title":"Mol Ther Oncol"},{"issue":"8","key":"10.1016\/j.seminoncol.2025.152454_bib0150","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11081198","article-title":"Clinical-scale production of CAR-T cells for the treatment of melanoma patients by mRNA transfection of a CSPG4-specific CAR under full GMP compliance","volume":"11","author":"Wiesinger","year":"2019","journal-title":"Cancers"},{"issue":"8","key":"10.1016\/j.seminoncol.2025.152454_bib0151","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.jcyt.2021.03.001","article-title":"Identification of novel HLA-restricted preferentially expressed antigen in melanoma peptides to facilitate off-the-shelf tumor-associated antigen-specific T-cell therapies","volume":"23","author":"Stanojevic","year":"2021","journal-title":"Cytotherapy"},{"issue":"6","key":"10.1016\/j.seminoncol.2025.152454_bib0152","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.ajpath.2024.02.012","article-title":"Alcaide P: deletion of MyD88 in T cells improves antitumor activity in melanoma","volume":"194","author":"Bayer","year":"2024","journal-title":"Am J Pathol"},{"issue":"9","key":"10.1016\/j.seminoncol.2025.152454_bib0153","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1007\/s11427-021-2078-6","article-title":"Stat5(-\/-) CD4(+) T cells elicit anti-melanoma effect by CD4(+) T cell remolding and Notch1 activation","volume":"65","author":"Jin","year":"2022","journal-title":"Sci China Life Sci"},{"issue":"5","key":"10.1016\/j.seminoncol.2025.152454_bib0154","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1089\/hum.2007.0171","article-title":"Adoptive cell therapy for patients with melanoma, using tumor-infiltrating lymphocytes genetically engineered to secrete interleukin-2","volume":"19","author":"Heemskerk","year":"2008","journal-title":"Human Gene Therapy"},{"key":"10.1016\/j.seminoncol.2025.152454_bib0155","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.biomaterials.2018.01.013","article-title":"Non-genetic engineering of cytotoxic T cells to target IL-4 receptor enhances tumor homing and therapeutic efficacy against melanoma","volume":"159","author":"Gunassekaran","year":"2018","journal-title":"Biomaterials"},{"issue":"10","key":"10.1016\/j.seminoncol.2025.152454_bib0156","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1158\/1078-0432.CCR-14-2085","article-title":"Tumor-infiltrating lymphocytes genetically engineered with an inducible gene encoding interleukin-12 for the immunotherapy of metastatic melanoma","volume":"21","author":"Zhang","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.seminoncol.2025.152454_bib0157","doi-asserted-by":"crossref","first-page":"3911","DOI":"10.1182\/blood.V112.11.3911.3911","article-title":"Treatment of large established murine melanoma with Th17 polarized CD4+ T helper cells genetically engineered to express MHC class II Restricted T cell receptor","volume":"112","author":"Muranski","year":"2008","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.seminoncol.2025.152454_bib0158","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/gt.2012.75","article-title":"Inhibition of TGF-\u03b2 signaling in genetically engineered tumor antigen-reactive T cells significantly enhances tumor treatment efficacy","volume":"20","author":"Zhang","year":"2013","journal-title":"Gene therapy"},{"issue":"6","key":"10.1016\/j.seminoncol.2025.152454_bib0159","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1038\/jid.2014.20","article-title":"TGF-\u03b2-induced (TGFBI) protein in melanoma: a signature of high metastatic potential","volume":"134","author":"Lauden","year":"2014","journal-title":"J Investigat Dermatol"},{"issue":"24","key":"10.1016\/j.seminoncol.2025.152454_bib0160","first-page":"8643","article-title":"Depletion of CD25+ CD4+ T cells and treatment with tyrosinase-related protein 2-transduced dendritic cells enhance the interferon \u03b1-induced, CD8+ T-cell-dependent immune defense of B16 melanoma","volume":"61","author":"Steitz","year":"2001","journal-title":"Cancer Res"},{"issue":"12","key":"10.1016\/j.seminoncol.2025.152454_bib0161","first-page":"4253","article-title":"Human dendritic cells genetically engineered to express a melanoma polyepitope DNA vaccine induce multiple cytotoxic T-cell responses","volume":"7","author":"Smith","year":"2001","journal-title":"Clin Cancer Res"},{"issue":"22","key":"10.1016\/j.seminoncol.2025.152454_bib0162","doi-asserted-by":"crossref","first-page":"5869","DOI":"10.1158\/1078-0432.CCR-20-1247","article-title":"Tebentafusp, a TCR\/anti-CD3 bispecific fusion protein targeting gp100, potently activated antitumor immune responses in patients with metastatic melanoma","volume":"26","author":"Middleton","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.seminoncol.2025.152454_bib0163","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.3390\/pharmaceutics16081046","article-title":"T cell-engaging bispecific antibodies targeting gp100 and PRAME: expanding application from uveal melanoma to cutaneous melanoma","volume":"16","author":"Reschke","year":"2024","journal-title":"Pharmaceutics"},{"issue":"11","key":"10.1016\/j.seminoncol.2025.152454_bib0164","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1016\/j.jid.2019.01.038","article-title":"Bispecific antibody approach for improved melanoma-selective PD-L1 immune checkpoint blockade","volume":"139","author":"Koopmans","year":"2019","journal-title":"J Investigat Dermatol"},{"issue":"5","key":"10.1016\/j.seminoncol.2025.152454_bib0165","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1158\/2159-8290.CD-21-0257","article-title":"Bispecific antibodies to PD-1 and CTLA4: doubling down on T cells to decouple efficacy from toxicity","volume":"11","author":"Burton","year":"2021","journal-title":"Cancer Dis"},{"key":"10.1016\/j.seminoncol.2025.152454_bib0166","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41591-025-03967-2","article-title":"Neoadjuvant PD-1 and LAG-3-targeting bispecific antibody and other immune checkpoint inhibitor combinations in resectable melanoma: the randomized phase 1b\/2 Morpheus-Melanoma trial","volume":"31","author":"Long","year":"2025","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.seminoncol.2025.152454_bib0167","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1007\/s10637-018-00719-7","article-title":"Bispecific anti-CD3 x anti-B7-H3 antibody mediates T cell cytotoxic ability to human melanoma in vitro and in vivo","volume":"37","author":"Ma","year":"2019","journal-title":"Investigat New Drugs"},{"issue":"1","key":"10.1016\/j.seminoncol.2025.152454_bib0168","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1002\/(SICI)1097-0215(19990105)80:1<138::AID-IJC25>3.0.CO;2-J","article-title":"Tumor-growth inhibition with bispecific antibody fragments in a syngeneic mouse melanoma model: the role of targeted T-cell co-stimulation via CD28","volume":"80","author":"Grosse-Hovest","year":"1999","journal-title":"Int J cancer"},{"issue":"5","key":"10.1016\/j.seminoncol.2025.152454_bib0169","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006436","article-title":"Bispecific antibodies redirect synthetic agonistic receptor modified T cells against melanoma","volume":"11","author":"M\u00e4rkl","year":"2023","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.seminoncol.2025.152454_bib0170","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1328368","article-title":"Automated manufacturing and characterization of clinical grade autologous CD20 CAR T cells for the treatment of patients with stage III\/IV melanoma","volume":"15","author":"Aleksandrova","year":"2024","journal-title":"Front Immunol"},{"issue":"13","key":"10.1016\/j.seminoncol.2025.152454_bib0171","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1016\/j.celrep.2017.09.002","article-title":"Augmentation of antitumor immunity by Human and mouse CAR T cells secreting IL-18","volume":"20","author":"Hu","year":"2017","journal-title":"Cell Rep"},{"issue":"640","key":"10.1016\/j.seminoncol.2025.152454_bib0172","doi-asserted-by":"crossref","first-page":"eabn2231","DOI":"10.1126\/scitranslmed.abn2231","article-title":"Oncolytic virus-mediated expansion of dual-specific CAR T cells improves efficacy against solid tumors in mice","volume":"14","author":"Evgin","year":"2022","journal-title":"Sci Transl Med"}],"container-title":["Seminars in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775425001460?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775425001460?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T17:07:59Z","timestamp":1773940079000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0093775425001460"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":172,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S0093775425001460"],"URL":"https:\/\/doi.org\/10.1016\/j.seminoncol.2025.152454","relation":{},"ISSN":["0093-7754"],"issn-type":[{"value":"0093-7754","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immuno-oncology approaches to overcome T cell exhaustion in melanoma","name":"articletitle","label":"Article Title"},{"value":"Seminars in Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.seminoncol.2025.152454","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"152454"}}